Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.39 |
| ▸ | ITGAV | P06756 | 2/20 | 0.39 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.35 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19213536 | 0.91 | EPHX1 (0.46) | NTRK1KMT2AMEN1MAPTITGB3 | |
| SCHEMBL5494715 | 0.90 | ITGB3 (0.36) | NTRK1KMT2AMAPTITGB3ITGAV | |
| SCHEMBL5499949 | 0.90 | KMT2A (0.36) | NTRK1KMT2AMEN1MAPTLMNA | |
| SCHEMBL5493399 | 0.90 | NTRK1 (0.39) | NTRK1KMT2AMEN1MAPTITGB3 | |
| Carbamic Acid SCHEMBL5493402 | 0.89 | NTRK1 (0.40) | NTRK1KMT2AMEN1MAPTITGB3 | |
| SCHEMBL5493337 | 0.89 | CYP2C9 (0.37) | NTRK1KMT2AKDM4ERAB9ATSHR | |
| SCHEMBL19399313 | 0.88 | NTRK1 (0.39) | NTRK1KMT2AMEN1MAPTITGB3 | |
| SCHEMBL5492718 | 0.87 | BCHE (0.40) | NTRK1LMNAPOLB | |
| SCHEMBL3121437 | 0.87 | NTRK1 (0.36) | NTRK1MAPTLMNASMN1; SMN2TSHR | |
| SCHEMBL3123213 | 0.86 | NTRK1 (0.35) | NTRK1KMT2AMEN1MAPTUTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112321610-B | Ceclozapine sulfate and preparation method and application thereof | 湖南润星制药有限公司 | 2022-04-19 | — | — | CN | claimed |
| CN-112321610-A | Ceclozapine sulfate and preparation method and application thereof | 湖南润星制药有限公司 | 2021-02-05 | — | — | CN | claimed |
| EP-3468968-B1 | SOLID FORMS OF CEFTOLOZANE AND PROCESSES FOR PREPARING | MERCK SHARP & DOHME LLC (US) | 2024-01-10 | — | — | EP | disclosed |
| US-11542279-B2 | Solid forms of ceftolozane and processes for preparing | MERCK SHARP & DOHME LLC (US) | 2023-01-03 | — | — | US | disclosed |
| CN-112321610-B | Ceclozapine sulfate and preparation method and application thereof | 湖南润星制药有限公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-112321610-B | Ceclozapine sulfate and preparation method and application thereof | 湖南润星制药有限公司 | 2022-04-19 | — | — | CN | disclosed |
| US-20220056045-A1 | SOLID FORMS OF CEFTOLOZANE AND PROCESSES FOR PREPARING | MERCK SHARP & DOHME CORP. (US) | 2022-02-24 | — | — | US | disclosed |
| CN-112321610-A | Ceclozapine sulfate and preparation method and application thereof | 湖南润星制药有限公司 | 2021-02-05 | — | — | CN | disclosed |
| CN-112321610-A | Ceclozapine sulfate and preparation method and application thereof | 湖南润星制药有限公司 | 2021-02-05 | — | — | CN | disclosed |
| EP-3347362-B1 | PROCESS FOR PREPARING CEFTOLOZANE FROM 7-AMINOCEPHALOSPORANIC ACID (7-ACA) | SANDOZ AG (CH) | 2019-10-23 | — | — | EP | disclosed |
| EP-3468968-A1 | SOLID FORMS OF CEFTOLOZANE AND PROCESSES FOR PREPARING | Merck Sharp & Dohme Corp. (US) | 2019-04-17 | — | — | EP | disclosed |
| US-9006421-B2 | Cephalosporin compositions and methods of manufacture | CUBIST PHARMACEUTICALS, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| EP-1556389-B3 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-04-01 | — | — | EP | disclosed |
| WO-2014152763-A1 | CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE | CUBIST PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140274958-A1 | CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE | MERCK SHARP & DOHME LLC | 2014-09-18 | — | — | US | disclosed |
| US-20140274999-A1 | CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE | MERCK SHARP & DOHME CORP. | 2014-09-18 | — | — | US | disclosed |
| EP-1556389-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2007-07-25 | — | — | EP | disclosed |
| US-20070037786-A1 | Cephem compounds | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-7129232-B2 | For therapy of of infectious diseases | ASTELLAS PHARMA INC. (JP) | 2006-10-31 | — | — | US | disclosed |
| US-20040132994-A1 | Cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037786-A1 | Cephem compounds | CEP170, ABCB11, SLC7A1 | NTRK1 2964/4885KMT2A 2510/4885MEN1 651/4885 |
| US-20040132994-A1 | Cephem compounds | CEP170, ABCB11, RCC2 | NTRK1 3809/4885KMT2A 2826/4885MEN1 868/4885 |
| US-20140274999-A1 | CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE | CYP3A7, SEPTIN7, PEPD | NTRK1 4368/4885KMT2A 1025/4885MEN1 612/4885 |
| US-20140274958-A1 | CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE | CYP3A7, SEPTIN7, PEPD | NTRK1 4368/4885KMT2A 1025/4885MEN1 612/4885 |
| US-11542279-B2 | Solid forms of ceftolozane and processes for preparing | PPP1CC, CCNC, AMPD3 | NTRK1 4563/4885KMT2A 1853/4885MEN1 2281/4885 |
| US-20220056045-A1 | SOLID FORMS OF CEFTOLOZANE AND PROCESSES FOR PREPARING | PPP1CC, CCNC, AMPD3 | NTRK1 4563/4885KMT2A 1853/4885MEN1 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.